
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
By now, most practices are familiar with Medicare's Correct CodingInitiative (CCI) introduced by CMS in 1996.



